NZ Neurology Research Review Issue 75

In this issue:
  -  SARS-CoV-2 serology after COVID-19 in pwMS
  -  Ocrelizumab attenuates antibody responses to SARS-CoV-2 infection
  -  Personalised extended interval dosing of ocrelizumab during the COVID-19 pandemic
  -  COVID-19 vaccine hesitancy in pwMS
  -  2021 MAGNIMS-CMSC-NAIMS consensus recommendations for MRI in MS
  -  Impact of common MS symptoms on HRQoL
  -  aHSCT as a first-line DMT in patients with ‘aggressive’ MS
  -  A real-world analysis of alemtuzumab vs cladribine for MS
  -  The impact of childhood tonsillectomy on JCV serological status in pwMS
  -  De-escalating rituximab dosage in pwMS

Please login below to download this issue (PDF)

Subscribe